Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 7/20 | 0.44 |
| ▸ | F7 | P08709 | 7/20 | 0.44 |
| ▸ | F3 | P13726 | 7/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 5/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | MASP2 | O00187 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31486413 | 0.91 | F2 (0.46) | F2F7F3CYP3A4CYP2C9 | |
| SCHEMBL31486457 | 0.88 | F2 (0.46) | F2F7F3CYP2C9NAMPT | |
| SCHEMBL31486275 | 0.87 | F3 (0.42) | F2F7F3PREP | |
| SCHEMBL30929487 | 0.83 | F2 (0.47) | F2F7F3RAB9ACYP3A4 | |
| SCHEMBL30929482 | 0.83 | F2 (0.47) | F2F7F3RAB9ACYP3A4 | |
| Trifluoroacetic Acid SCHEMBL31486347 | 0.83 | F2 (0.39) | F2RAB9ACYP3A4CYP2C9CYP2C19 | |
| Trifluoroacetic Acid SCHEMBL31486265 | 0.81 | F7 (0.55) | F2F7F3 | |
| SCHEMBL31486498 | 0.78 | F2 (0.47) | F2F7F3CYP2C9NAMPT | |
| SCHEMBL31486238 | 0.78 | F7 (0.43) | F2F7F3PREP | |
| SCHEMBL31486309 | 0.77 | F2 (0.45) | F2F3NAMPTP2RX7MASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025076476-A2 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, SPINT2, SERPINB1 | F2 117/4885F7 1426/4885F3 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.